Feature | January 31, 2014

Improved Ultrasound Imaging Provides Alternative Tumor Visualization

Ultrasound Systems Contrast Media Clinical Study Tumor Visualization
January 31, 2014 — Researchers at the University of North Carolina at Chapel Hill have achieved higher resolution ultrasounds that can help detect tumors. 
 
They combined ultrasound with a contrast agent comprised of micro-sized bubbles that pair with an antibody produced at elevated levels by many cancers. By binding to the protein SFRP2, the microbubble contrast agent greatly improves the resolution and tumor-detecting ability of scans produced by ultrasound. 
 
In a paper published by PLOS-ONE, UNC Lineberger Comprehensive Cancer Center members Nancy Klauber-DeMore, M.D., professor of surgery, and Paul Dayton, Ph.D., professor of biomedical engineering, were able to visualize lesions created by angiosarcoma, a malignant cancer that develops on the walls of blood vessels.
 
“The SFRP2-moleculary targeted contrast agent showed specific visualization of the tumor vasculature,” Klauber-DeMore said. “In contrast, there was no visualization of normal blood vessels. This suggests that the contrast agent may help to distinguish malignant from benign masses found on imaging.”
 
Klauber-DeMore’s lab discovered that angiosarcoma cells produce an excess of SFRP2, and her team focused on how to use the protein to better monitor the progress of the cancer within blood vessels. Using a pre-clinical model, the researchers delivered the microbubble contrast agent via intravenous injection and tracked it using ultrasound.
 
SFRP2 is expressed in many cancer, including breast, colon, pancreas, ovarian and kidney tumors, making the technique potentially useful on a broad range of cancer types. Klauber-DeMore said that the next steps of her research team will involve determining how well the technique works with these tumor types, as well as studying its effect on breast cancer.
 
Research indicates the level of SFRP2 expressed by tumors increases as they develop, and the team will investigate whether the technique can be used to track tumor growth and chemotherapy response. The researchers will also investigate whether it can be used to detect and visualize very small tumors.
 
Ultrasound is less expensive than commonly used imaging methods like magnetic resonance imaging (MRI), and the technique could lower costs to patients being treated for cancer. Ultrasound portability may enable treatment in rural and low-resource areas.
 
For more information: www.plosone.com

Related Content

Breast Cancer Follow-up Imaging Varies Widely
News | Breast Imaging | July 13, 2018
July 13, 2018 — Follow-up imaging for women...
Siemens Healthineers Launches Acuson Sequoia Ultrasound
Technology | Ultrasound Imaging | July 12, 2018
July 12, 2018 — Siemens Healthineers recently announced the launch of its new ultrasound system, the Acuson Sequoia.
EchoNous Vein Receives FDA Approval to Improve First-Time Peripheral IV Catheter Insertion
Technology | Ultrasound Imaging | July 12, 2018
EchoNous has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the EchoNous Vein, an ultrasound-...
Lack of Insurance Coverage Delaying Proton Therapy Clinical Trials
News | Proton Therapy | July 12, 2018
Randomized clinical trials are the gold standard of cancer research and can shed light on whether innovative, new...
Breast Cancer Studies Ignore Race, Socioeconomic Factors
News | Women's Health | July 11, 2018
A new commentary appearing in the July issue of Cancer Causes & Control points to evidence that social factors help...
Hologic Announces Availability of Viera Portable Breast Ultrasound System
Technology | Ultrasound Women's Health | July 11, 2018
Hologic’s new Viera portable breast ultrasound system is now available for purchase in the United States and Europe....
Guerbet, IBM Watson Health Partner on Artificial Intelligence for Liver Imaging
News | Clinical Decision Support | July 10, 2018
Guerbet announced it has signed an exclusive joint development agreement with IBM Watson Health to develop an...
Healcerion Receives FDA Approval for Sonon 300L Handheld Ultrasound Device
Technology | Ultrasound Imaging | July 09, 2018
South Korea-based Healcerion launched the Sonon 300L wireless handheld ultrasound device to the U.S. market following U...
High-Strength MRI May Release Mercury from Amalgam Dental Fillings
News | Magnetic Resonance Imaging (MRI) | July 05, 2018
Exposure to ultra-high-strength magnetic resonance imaging (MRI) may release toxic mercury from amalgam fillings in...
Overlay Init